CN1299585C - Milk powder for preventing and improving cardio-cerebral vascular diseases and its preparing method - Google Patents
Milk powder for preventing and improving cardio-cerebral vascular diseases and its preparing method Download PDFInfo
- Publication number
- CN1299585C CN1299585C CNB02158673XA CN02158673A CN1299585C CN 1299585 C CN1299585 C CN 1299585C CN B02158673X A CNB02158673X A CN B02158673XA CN 02158673 A CN02158673 A CN 02158673A CN 1299585 C CN1299585 C CN 1299585C
- Authority
- CN
- China
- Prior art keywords
- milk
- fresh milk
- ginger
- add
- milk powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 92
- 239000008267 milk Substances 0.000 title claims abstract description 92
- 210000004080 milk Anatomy 0.000 title claims abstract description 92
- 239000000843 powder Substances 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 18
- 208000019553 vascular disease Diseases 0.000 title abstract 6
- 241000234314 Zingiber Species 0.000 claims abstract description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 16
- 235000008397 ginger Nutrition 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 20
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 19
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 19
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- 235000020185 raw untreated milk Nutrition 0.000 claims description 13
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 11
- 239000011669 selenium Substances 0.000 claims description 11
- 229910052711 selenium Inorganic materials 0.000 claims description 11
- 235000011649 selenium Nutrition 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 10
- 239000011651 chromium Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 229910052804 chromium Inorganic materials 0.000 claims description 9
- 229940050168 zinc lactate Drugs 0.000 claims description 9
- 235000000193 zinc lactate Nutrition 0.000 claims description 9
- 239000011576 zinc lactate Substances 0.000 claims description 9
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 8
- 239000001527 calcium lactate Substances 0.000 claims description 8
- 229960002401 calcium lactate Drugs 0.000 claims description 8
- 235000011086 calcium lactate Nutrition 0.000 claims description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 8
- 229960001231 choline Drugs 0.000 claims description 8
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000084 colloidal system Substances 0.000 claims description 8
- 235000013925 ferrous lactate Nutrition 0.000 claims description 8
- 239000004225 ferrous lactate Substances 0.000 claims description 8
- 229940037907 ferrous lactate Drugs 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 235000020708 ginger extract Nutrition 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 239000011664 nicotinic acid Substances 0.000 claims description 8
- 235000001968 nicotinic acid Nutrition 0.000 claims description 8
- 229940055726 pantothenic acid Drugs 0.000 claims description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims description 8
- 239000011713 pantothenic acid Substances 0.000 claims description 8
- 229960005055 sodium ascorbate Drugs 0.000 claims description 8
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 8
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 8
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940091258 selenium supplement Drugs 0.000 claims description 4
- -1 sterilize Substances 0.000 claims description 2
- 229940002508 ginger extract Drugs 0.000 claims 5
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims 2
- 239000001116 FEMA 4028 Substances 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
- 229960004853 betadex Drugs 0.000 claims 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- 229940107218 chromium Drugs 0.000 claims 1
- 238000010411 cooking Methods 0.000 claims 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims 1
- 229940107187 fructooligosaccharide Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 6
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 abstract description 6
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 abstract description 6
- 235000002780 gingerol Nutrition 0.000 abstract description 6
- 229940088594 vitamin Drugs 0.000 abstract description 6
- 229930003231 vitamin Natural products 0.000 abstract description 6
- 235000013343 vitamin Nutrition 0.000 abstract description 6
- 239000011782 vitamin Substances 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- 230000001954 sterilising effect Effects 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 108010007622 LDL Lipoproteins Proteins 0.000 description 12
- 238000011010 flushing procedure Methods 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 10
- 235000020183 skimmed milk Nutrition 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- 235000014121 butter Nutrition 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000007872 degassing Methods 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000005057 refrigeration Methods 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 238000000889 atomisation Methods 0.000 description 5
- 239000011552 falling film Substances 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000003035 anti-peroxidant effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to milk powder capable of effectively preventing and improving cardio-cerebral vascular diseases and a preparing method thereof. The inventor of the present invention regulates the proportion of each nutrient in the milk powder according to the physiological and biochemical characteristics of high risk groups and patients with cardio-cerebral vascular diseases, and simultaneously, various vitamins, microelements and other active constituents having a close relation with the cardio-cerebral vascular diseases are added, particularly gingerol belonging to the active component of ginger and resisting the cardio-cerebral vascular diseases is added. The milk powder is an excellent accessory food for the high risk groups and the patients with the cardio-cerebral vascular diseases.
Description
(1) technical field
The present invention relates to a kind of milk powder and its manufacture method that can effectively prevent and improve cardiovascular and cerebrovascular disease.
(2) background technology
Milk powder is common nutraceutical, but appears in the newspapers at the milk powder of cardiovascular and cerebrovascular disease specially.Gingerol in the ginger has the absorption of inhibition human body to cholesterol, prevent that liver and serum cholesterol from accumulating softening blood vessel, antiatherosclerosis, blood fat-reducing blood pressure-decreasing, the anti-platelet aggregation effect, anti peroxidation of lipid improves effects such as brain circulatory function, and the deep processing of ginger is confined to flavouring and pot foods, the functional food of relevant ginger does not appear in the newspapers yet, and therefore, the prevention of ginger and the function of improving cardiovascular and cerebrovascular disease also do not obtain development and use.
(3) summary of the invention
[problem that will solve]
The objective of the invention is to utilize the health care of ginger, a kind of milk powder that can effectively prevent and improve cardiovascular and cerebrovascular disease is provided.Another object of the present invention provides a kind of manufacture method of this milk powder.
[technical scheme]
The inventor designs at the cardiovascular and cerebrovascular disease pathogenesis.Regulated the ratio of each nutrient meticulously according to cardiovascular and cerebrovascular disease people at highest risk and patient's nutritional characteristic, having added multiple and cardiovascular and cerebrovascular disease simultaneously has the vitamin and the trace element of substantial connection, particularly introduced the active component gingerol of resisting cardiovascular disease, finished the present invention thus by adding Ginger P.E.
The invention provides a kind of milk powder that prevents and improve cardiovascular and cerebrovascular disease, it is characterized in that containing Ginger P.E in this milk powder.In one embodiment of the invention, every 100kg fresh milk of making this milk powder is equipped with 10kg, 25kg or 35kg Ginger P.E.The preparation method of described Ginger P.E is: get ginger, clean, be cut into the thin slice of 2～3cm, the water that adds 1.5 times of amounts adds sodium ascorbate 0.1%, grinds in the colloid mill cocycle, increase the fineness of grinding gradually, under 140 eye mesh screens, filter, residue water flushing 3 times, flushing liquor is incorporated in the filtrate, make the filtrate homogeneous under the 200Mpa, the degassing is 90 ℃ of following sterilizations, 10 minutes, then 8 ℃ of refrigerations down.
In another embodiment of the invention, milk powder of the present invention also contains β～cyclodextrin, FOS, honey, ascorbic acid, nicotinic acid, Cobastab
6, Cobastab
12, vitamin E, folic acid, pantothenic acid, choline, nicotinic acid chromium, zinc lactate, yeast selenium, ferrous lactate, calcium lactate.The preferred content of each component is also to contain beta-schardinger dextrin-0.5～1.5kg, FOS 2～4kg, honey 5～15kg, ascorbic acid 100～170g, nicotinic acid B 5～10g, Cobastab in every 100kg milk powder
60.5～1.0g, Cobastab
120.3～0.7mg, vitamin e1 0～20g, folic acid 200～400mg, pantothenic acid 0.5～1.0g, choline 150～300g, nicotinic acid chromium 100～200mg, zinc lactate 4～9g, yeast selenium 10～30mg, ferrous lactate 5～10g, calcium lactate 50～90g.
The present invention is a primary raw material with natural pasture high-quality fresh milk, use therein fresh milk have following technical indicator: energy 〉=1.785MJ (〉=420kcal); Protein 〉=21g (accounting for gross energy) than 24%; Fat≤14g (accounting for gross energy) than 16%; Carbohydrate (main lactose) 〉=52.5g (accounting for gross energy) than 60%.
As mentioned above, gingerol has and suppresses the absorption of human body to cholesterol, prevents that liver and serum cholesterol from accumulating, softening blood vessel, and antiatherosclerosis, blood fat-reducing blood pressure-decreasing, the anti-platelet aggregation effect, anti peroxidation of lipid improves effects such as brain circulatory function.
Trace element chromium (Cr
3+) can significantly improve the lipid-metabolism of hyperlipemia, and be dose-dependence.Only contain the chromium that total amount is 6～7mg in the normal human, the height of chromium concn level has direct relation with food in the human body.Chromium can a large amount of forfeitures in food processing and refining process.On the other hand, human body is taken in these purified diets in a large number, also can impel a large amount of drainages that store chromium in the body.It is reported, most of food chrome contents all are less than 16 μ g/g, the cr intake that the chromium amount of taking the photograph of finding most cardiovascular and cerebrovascular disease patients simultaneously all is lower than the nearly all cardiovascular and cerebrovascular disease patient of the lower limit of nutrition mechanism defined all is less than 50 μ g/d, and this is significantly less than 50～200 μ g/d that nutrition mechanism is recommended.Added the nicotinic acid chromium that is easy to absorption of human body in the milk powder of the present invention.
Vitamin C has lipoid peroxidization resistant, also is a kind of effective free radical scavenger, can also reduce cholesterolemia, improves HDL (HDL) content, reduces the fatal rate of cardiovascular and cerebrovascular disease.Vitamin E has the atherosclerotic effect that prevents, can delay the LDL oxidation, suppresses vascular smooth muscle cell proliferation, suppresses PA and aggegation, suppresses the expression and the function of adhesion molecule, reduces the release of synthesizing and strengthen prostacyclin of leukotriene.
Zinc can be kept the integrality of vascular endothelial cell, the anti-vascular endothelial cell apoptosis, and lipotropism matter or inflammatory cytokine are to the damaging action of endothelium.Added the zinc lactate that is easy to absorption of human body in the milk powder of the present invention.
Selenium is as free radical scavenger; can directly or by the indirectly-acting of glutathione peroxidase remove free radical; stop peroxidatic reaction of lipid; thereby prevent that cardiac muscle cell and cell membrane from avoiding its damage, protection cardiac muscle cell's the stability and the normal configuration and the function of normal permeability and cardiac muscular tissue.Added the yeast selenium that is easy to absorption of human body in the milk powder of the present invention.
FOS can reduce body inner cholesterol, triglyceride, free fatty and blood sugar quantity effectively, prevents atherosclerotic and hypertensive generation.
The invention provides a kind of manufacture method of preventing and improving the milk powder of cardiovascular and cerebrovascular disease, this method may further comprise the steps:
A) prepare fresh milk: the raw milk to acceptance(check) is carried out preliminary treatment and standardization;
B) preparation Ginger P.E: get ginger, clean, be cut into the thin slice of 2～3cm, the water that adds 1.5 times of amounts adds sodium ascorbate 0.1%, grinds in the colloid mill cocycle, increase the fineness of grinding gradually, under 140 eye mesh screens, filter, residue water flushing 3 times, flushing liquor is incorporated in the filtrate, make the filtrate homogeneous under the 200Mpa, the degassing is 90 ℃ of following sterilizations, 10 minutes, then 8 ℃ of refrigerations down;
C) batching: add Ginger P.E in fresh milk, stirring makes fresh milk mixt;
D) preparation milk powder: with above-mentioned fresh milk mixt homogeneous, sterilization concentrates, spray-drying, cooling sieve powder.
In a preferred embodiment, the c of described method) in the batching step, also comprises water dissolving nicotinic acid, Cobastab before adding Ginger P.E
6, Cobastab
12, vitamin E, folic acid, pantothenic acid, the mixture of choline joins in the fresh milk; Water dissolving nicotinic acid chromium, zinc lactate, yeast selenium, ferrous lactate, calcium lactate 70g joins in the fresh milk; Water dissolving ascorbic acid joins in the fresh milk; β～cyclodextrin directly joins in the fresh milk in batches; Ginger P.E, FOS and honey also will join in the fresh milk in batches.
Wherein said preliminary treatment comprises carries out antibiotic and acidity check to raw milk, and the removal of impurity, wherein said standardization comprise that the content of adjusting butter oil is 2/3rds of normal breast.
Wherein said homogeneous adopts two sections homogeneous of homogenizer, the about 200Mpa of homogenization pressure.Wherein said sterilization is at sterilization 3～6min below 95 ℃.
Wherein said concentrated employing double-effect falling film evaporator, an effect evaporating temperature is 70～76 ℃, two effect evaporating temperatures are 48～52 ℃.
The about 120Mpa of atomisation pressure that adopts in the wherein said spray-drying.
Temperature of outgoing air is 72～75 ℃ in the wherein said cooling sieve powder; EAT is 150～180 ℃.
D of the present invention) preparation milk powder step can be finished according to conventional steps well known by persons skilled in the art.
[beneficial effect]
Milk is the high nutrient that a kind of generally acknowledged helping prevented and improved cardiovascular and cerebrovascular disease, is very suitable selection with this as basic nutrition material and carrier; The use of uniting of gingerol and Organic Chromium has cooperative effect to preventing and improving cardiovascular and cerebrovascular disease, has stronger effect aspect reduction blood fat, Green Tea Extract and inhibition and the reparation atherosclerotic; Amino acid that is rich in the product and ascorbic acid have improved the transhipment and the absorption of chromium in the body again; Morbidity has the interpolation of nutrient～trace element zinc, selenium and the compound sugar etc. of positive role further to strengthen the health-care effect of product again to the prevention cardiovascular and cerebrovascular disease.
Through zoopery and analysis, prove that product of the present invention has the excellent prevention effect to cardiovascular and cerebrovascular disease.The standard ethanol extract of ginger shows the result of the test that influences of mouse (E (the 0)) progression of atherosclerosis that apolipoprotein-E lacks, and feeds every day and raises 250 μ g Ginger P.Es (wherein total gingerol content 40mg/g; Total shogaol content 90mg/g; Essential oil content 14 μ g/g) mouse aorta sclerosis damage has reduced by 44% (P＜0.01), plasma triglyceride has descended 27%, plasma cholesterol has descended 29%, triglycerides and cholesterol have descended 36% and 53% respectively among the VLDL, triglycerides and cholesterol 58% and 33% (P＜0.01) that descended respectively among the LDL.This result with in 10 weeks hello raise cholesterol in the peritoneal macrophages of E (0) mouse of heavy dose of Ginger P.E biosynthesis rate 76% relevant (P＜0.01) that descended.In addition, feed the ability lower (being respectively 43% and 47%) of the peritoneal macrophages oxidation LDL that E (0) mouse raise 25 or 250 μ g Ginger P.Es obtains from every day.Feed every day and raise the basic horizontal decline 62% that 250 μ g Ginger P.Es can make the mouse lipid peroxide relevant with LDL, simultaneously, also can make LDL agglutinating reaction (causing), this is also had 33% inhibitory action (P＜0.01) by eddy current effect.According to experimental result, think that Ginger P.E can reduce development of atherosclerosis, this be since Ginger P.E may reduce macrophage to the oxidation of LDL, reduce macrophage to the state of oxidation of engulfing, alleviate LDL of ox-LDL and the gathering of LDL.More than these effects can cause that the cell inner cholesterol is accumulated, the mark of foam cells and early atherosclerosis reduces.Hence one can see that raises Ginger P.E and can obviously alleviate atherosclerotic lesions by feeding to mouse.This study of anti-atherogenic effect is relevant with cholesterol levels decline among blood plasma and the LDL, has obviously reduced the basic oxidation state of LDL, and LDL has also had obvious decline to the sensitiveness of oxidation reaction and agglutinating reaction simultaneously.This product is fed the treated animal of raising this product and is quite fed LDL and all obviously reductions (P＜0.05) of T-CHOL of raising this product rat through the experiment of Wistar male rat; Do not feed and raise this product rat animal sustainer microscopically and observe and have tangible Atheromatosis reason to change, raise this product treated animal and do not have this change and feed.Therefore product of the present invention is cardiovascular and cerebrovascular disease people at highest risk and the good accesary foods of patient.
In addition, the present invention is that primary raw material adopts the economic benefits and social benefits vacuum to concentrate and the manufacturing of pressure spray dryer technology with natural pasture high-quality fresh milk, and the product heated time is short, particle is big, instant capacity is good, and milk is strong, has kept the physiologically active of function factor in the local flavor of fresh milk and the product largely.
(4) specific embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
A) prepare fresh milk
Raw milk to acceptance(check) will be carried out preliminary treatment, comprises filtration, purifies and cooling, to remove the impurity in Ruzhong.Standardization makes butter oil content be controlled at 2.9%.Concrete standardized method is carried out according to the method for conventional milk plant.
B) preparation Ginger P.E
Get the 25kg ginger, clean, be cut into the thin slice of 2～3cm, the water that adds 1.5 times of amounts adds sodium ascorbate 0.1%, grinds in the colloid mill cocycle, increase the fineness of grinding gradually, under 140 eye mesh screens, filter, residue water flushing 3 times, flushing liquor is incorporated in the filtrate, make the filtrate homogeneous under the 200Mpa, the degassing is 90 ℃ of following sterilizations, 10 minutes, then 8 ℃ of refrigerations down.
C) batching
β～cyclodextrin 1kg is directly joined in the fresh milk in batches.Stir after 5 minutes, add 25 kilogram of raw ginger extracts, continue to stir 8 minutes, make fresh milk mixt.
D) preparation milk powder
With above-mentioned fresh milk mixt two sections homogeneous (homogenization pressure 200Mpa) on homogenizer, then at 95 ℃ of following sterilization 5min.The employing double-effect falling film evaporator concentrates, and an effect evaporating temperature is 73 ℃, and two effect evaporating temperatures are 50 ℃.Then under the 120Mpa atomisation pressure, use the spray dryer spray-drying.73 ℃ of temperature of outgoing airs, EAT cools off the sieve powder down for 160 ℃.Obtain the 100kg final products.
Embodiment 2
A) prepare fresh milk
Raw milk to acceptance(check) will be carried out preliminary treatment, comprises filtration, purifies and cooling, to remove the impurity in Ruzhong.Standardization requires butter oil content to reduce to 2/3rds (about 1.9%) of raw material milk butter oil, and standardized means can adopt earlier carries out the butterfat separation to raw milk, carries out composite then as calculated according to a certain percentage; Another kind method can adopt the interpolation skimmed milk powder to carry out standardization.The content's index of cream and skimmed milk powder is not fixed because the skimmed milk after raw milk, butterfat separate is congratulated somebody on a happy occasion, standardization again after needing temporarily to calculate.
B) preparation Ginger P.E
Get the 25kg ginger, clean, be cut into the thin slice of 2～3cm, the water that adds 1.5 times of amounts adds sodium ascorbate 0.1%, grinds in the colloid mill cocycle, increase the fineness of grinding gradually, under 140 eye mesh screens, filter, residue water flushing 3 times, flushing liquor is incorporated in the filtrate, make the filtrate homogeneous under the 200Mpa, the degassing is 90 ℃ of following sterilizations, 10 minutes, then 8 ℃ of refrigerations down.
C) batching
With nicotinic acid B 7.8g, Cobastab
60.74g, Cobastab
120.5mg, vitamin e1 6.0g, folic acid 289mg, pantothenic acid 0.7g, the mixture of choline 215g dissolves with 1000 ml waters, joins in the 100kg fresh milk.
With nicotinic acid chromium 150mg, zinc lactate 6.5g, yeast selenium 20.0mg, ferrous lactate 7.5g, calcium lactate 70g dissolves with 1000 ml waters, joins in the fresh milk.
Ascorbic acid 135.0g is dissolved with 500 ml waters, join in the fresh milk.
β～cyclodextrin 1kg is directly joined in the fresh milk in batches.Stir after 5 minutes, add 25 kilogram of raw ginger extracts, continue to stir 8 minutes.
With FOS 3kg with join in the fresh milk in batches.Honey 10kg (about water content 70%) also directly joins in the fresh milk in batches.
Said mixture is stirred, make fresh milk mixt.
D) preparation milk powder
With above-mentioned fresh milk mixt two sections homogeneous (homogenization pressure 200Mpa) on homogenizer, then at 95 ℃ of following sterilization 5min.The employing double-effect falling film evaporator concentrates, and an effect evaporating temperature is 73 ℃, and two effect evaporating temperatures are 50 ℃.Then under the 120Mpa atomisation pressure, use the spray dryer spray-drying.73 ℃ of temperature of outgoing airs, EAT cools off the sieve powder down for 160 ℃.Obtain the 100kg final products.
Embodiment 3
A) prepare fresh milk
Raw milk to acceptance(check) will be carried out preliminary treatment, comprises filtration, purifies and cooling, to remove the impurity in Ruzhong.Standardization requires butter oil content to reduce to 2/3rds (about 1.9%) of raw material milk butter oil, and standardized means can adopt earlier carries out the butterfat separation to raw milk, carries out composite then as calculated according to a certain percentage; Another kind method can adopt the interpolation skimmed milk powder to carry out standardization.The content's index of cream and skimmed milk powder is not fixed because the skimmed milk after raw milk, butterfat separate is congratulated somebody on a happy occasion, standardization again after needing temporarily to calculate.
B) preparation Ginger P.E
Get the 10kg ginger, clean, be cut into the thin slice of 2～3cm, the water that adds 1.5 times of amounts adds sodium ascorbate 0.1%, grinds in the colloid mill cocycle, increase the fineness of grinding gradually, under 140 eye mesh screens, filter, residue water flushing 3 times, flushing liquor is incorporated in the filtrate, make the filtrate homogeneous under the 200Mpa, the degassing is 90 ℃ of following sterilizations, 10 minutes, then 8 ℃ of refrigerations down.
C) batching
With nicotinic acid 5g, Cobastab
60.5g, Cobastab
120.7mg, vitamin E2 0.0g, folic acid 400mg, pantothenic acid 0.5g, the mixture of choline 150g dissolves with 1000 ml waters, joins in the 100kg fresh milk.
With nicotinic acid chromium 100mg, zinc lactate 9g, yeast selenium 10.0mg, ferrous lactate 10g, calcium lactate 50g dissolves with 1000 ml waters, joins in the fresh milk.
Ascorbic acid 170.0g is dissolved with 500 ml waters, join in the fresh milk.
β～cyclodextrin 0.5kg is directly joined in the fresh milk in batches.Stir after 5 minutes, add the 10kg Ginger P.E, continue to stir 8 minutes.
With FOS 4kg with join in the fresh milk in batches.Honey 15kg (about water content 70%) also directly joins in the fresh milk in batches.
Said mixture is stirred, make fresh milk mixt.
D) preparation milk powder
With above-mentioned fresh milk mixt two sections homogeneous (homogenization pressure 200Mpa) on homogenizer, then at 95 ℃ of following sterilization 5min.The employing double-effect falling film evaporator concentrates, and an effect evaporating temperature is 73 ℃, and two effect evaporating temperatures are 50 ℃.Then under the 120Mpa atomisation pressure, use the spray dryer spray-drying.73 ℃ of temperature of outgoing airs, EAT cools off the sieve powder down for 160 ℃.Obtain the 100kg final products.
Embodiment 4
A) prepare fresh milk
Raw milk to acceptance(check) will be carried out preliminary treatment, comprises filtration, purifies and cooling, to remove the impurity in Ruzhong.Standardization requires butter oil content to reduce to 2/3rds (about 1.9%) of raw material milk butter oil, and standardized means can adopt earlier carries out the butterfat separation to raw milk, carries out composite then as calculated according to a certain percentage; Another kind method can adopt the interpolation skimmed milk powder to carry out standardization.The content's index of cream and skimmed milk powder is not fixed because the skimmed milk after raw milk, butterfat separate is congratulated somebody on a happy occasion, standardization again after needing temporarily to calculate.
B) preparation Ginger P.E
Get the 35kg ginger, clean, be cut into the thin slice of 2～3cm, the water that adds 1.5 times of amounts adds sodium ascorbate 0.1%, grinds in the colloid mill cocycle, increase the fineness of grinding gradually, under 140 eye mesh screens, filter, residue water flushing 3 times, flushing liquor is incorporated in the filtrate, make the filtrate homogeneous under the 200Mpa, the degassing is 90 ℃ of following sterilizations, 10 minutes, then 8 ℃ of refrigerations down.
C) batching
With nicotinic acid 10g, Cobastab
61.0g, Cobastab
120.3mg, vitamin e1 0g, folic acid 200mg, pantothenic acid 1.0g, the mixture of choline 300g dissolves with 1000 ml waters, joins in the 100kg fresh milk.
With nicotinic acid chromium 200mg, zinc lactate 4g, yeast selenium 30.0mg, ferrous lactate 5g, calcium lactate 90g dissolves with 1000 ml waters, joins in the fresh milk.
Ascorbic acid 100.0g is dissolved with 500 ml waters, join in the fresh milk.
β～cyclodextrin 1.5kg is directly joined in the fresh milk in batches.Stir after 5 minutes, add 35 kilogram of raw ginger extracts, continue to stir 8 minutes.
With FOS 2kg with join in the fresh milk in batches.Honey 5kg (about water content 70%) also directly joins in the fresh milk in batches.
Said mixture is stirred, make fresh milk mixt.
D) preparation milk powder
With above-mentioned fresh milk mixt two sections homogeneous (homogenization pressure 200Mpa) on homogenizer, then at 95 ℃ of following sterilization 5min.The employing double-effect falling film evaporator concentrates, and an effect evaporating temperature is 73 ℃, and two effect evaporating temperatures are 50 ℃.Then under the 120Mpa atomisation pressure, use the spray dryer spray-drying.73 ℃ of temperature of outgoing airs, EAT cools off the sieve powder down for 160 ℃.Obtain the 100kg final products.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02158673XA CN1299585C (en) | 2002-12-27 | 2002-12-27 | Milk powder for preventing and improving cardio-cerebral vascular diseases and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02158673XA CN1299585C (en) | 2002-12-27 | 2002-12-27 | Milk powder for preventing and improving cardio-cerebral vascular diseases and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511459A CN1511459A (en) | 2004-07-14 |
| CN1299585C true CN1299585C (en) | 2007-02-14 |
Family
ID=34237130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02158673XA Expired - Fee Related CN1299585C (en) | 2002-12-27 | 2002-12-27 | Milk powder for preventing and improving cardio-cerebral vascular diseases and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1299585C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104472708A (en) * | 2014-11-26 | 2015-04-01 | 东北农业大学 | Milk powder capable of preventing and treating woman climacteric syndrome diseases and preparation method of milk powder |
| CN108812916B (en) * | 2018-05-23 | 2022-01-18 | 新疆旺源驼奶实业有限公司 | Camel milk tablet with auxiliary blood sugar reducing function and preparation method thereof |
| CN113080263A (en) * | 2020-01-09 | 2021-07-09 | 武汉酷尔生物科技有限公司 | Adult milk powder for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN115702906B (en) * | 2021-08-09 | 2024-09-24 | 深圳奥萨制药有限公司 | Composition for preventing and improving cardiovascular diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107297A (en) * | 1994-11-25 | 1995-08-30 | 孙淑芝 | Carrot and potato milk |
| CN1338216A (en) * | 2000-08-17 | 2002-03-06 | 郭立文 | Nutritive food for recovery |
| EP1201132A1 (en) * | 1999-08-03 | 2002-05-02 | Kabushiki Kaisha Yakult Honsha | Fermented milk drinks and foods and process for producing the same |
-
2002
- 2002-12-27 CN CNB02158673XA patent/CN1299585C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107297A (en) * | 1994-11-25 | 1995-08-30 | 孙淑芝 | Carrot and potato milk |
| EP1201132A1 (en) * | 1999-08-03 | 2002-05-02 | Kabushiki Kaisha Yakult Honsha | Fermented milk drinks and foods and process for producing the same |
| CN1338216A (en) * | 2000-08-17 | 2002-03-06 | 郭立文 | Nutritive food for recovery |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1511459A (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1468066A (en) | Method for dispersing phytosterols for beverages and phytosterol-dispersed beverages having nanoscale particle size in dispersed beverages | |
| CN1553805A (en) | Nutritional composition for controlling blood glucose levels | |
| CN105982331A (en) | Universal type aquatic collagen peptide food for wound healing | |
| CN102948483A (en) | Blood fat reducing milk powder and preparation method thereof | |
| CN1692782A (en) | Sour milk pellets with lowering blood-pressure function | |
| CN1299585C (en) | Milk powder for preventing and improving cardio-cerebral vascular diseases and its preparing method | |
| CN102579641A (en) | Composition for protecting lever and achieving sobering function | |
| CN100337662C (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN1299694C (en) | Flavone composition for sobering and liver protection and its use | |
| CN1557842A (en) | Extraction method, pharmaceutical preparation preparation method and application of polygonatum polysaccharide | |
| CN1479578A (en) | Anticholesterolemic Edible Oils | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1606917A (en) | Method for extracting lactalbumin and separating different active ingredient of lactalbumin | |
| JP6485846B2 (en) | NAFLD / NASH preventive and / or therapeutic agent | |
| CN101971942B (en) | Nitrogen source reinforced oral liquid containing peptide and oligosaccharide and preparation method thereof | |
| CN1225175C (en) | Milk for lowering sugar and producing method | |
| CN117678642A (en) | A composition that helps maintain healthy levels of blood lipids and preparation method thereof | |
| CN1254251C (en) | Composition of pharmaceutical and preparation process thereof | |
| CN1305405C (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| AU2023387778A1 (en) | Coated algae powder for adding to dairy cow feed and dairy cow feed | |
| CN1108111C (en) | Hypolipemic rice-flour noodles and its preparing process | |
| CN1742783A (en) | Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method | |
| JP2012188426A (en) | Lipid metabolism-improving composition | |
| CN119817810A (en) | Formula food with special medical application and preparation method and application thereof | |
| CN1282473C (en) | Wild chrysanthemum granules and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070214 Termination date: 20100127 |